Structural Bioinformatics and ChemNavigator form allianceSan Diego 05 September 2001 Structural Bioinformatics and ChemNavigator agreedto combine SBI's proprietary technologies in three-dimensional computational proteomics with ChemNavigator's proprietary technologies in chemistry. The collaborative agreement will facilitate the rapid identification of new drug candidates. Under the terms of the agreement, SBI and its customers can use ChemNavigator's 3-D database of two million drug-like compounds to screen in silico against the 2600 3-D proprietary protein structures in SBI's drug target database. SBI and ChemNavigator will share in revenues generated from the combined use of their technologies.
SBI will offer customers access to ChemNavigator's database through SBI's Genes
to Leads service, which rapidly identifies new drug candidates, while
reducing synthesis and acquisition by 100-1,000 fold. Employing advanced
supercomputer technology, SBI converts nucleic acid or amino acid sequences of
clinically relevant drug targets into 3-D protein structures of x-ray
crystallographic quality. The company then maps the binding sites for potential
drug candidates, creating templates for high-throughput virtual screening of
large 3-D databases of compounds. This service increases the probability of
identifying molecules with greater specificity, more effectively harnessing the
full range of molecular diversity.
ChemNavigator brings its powerful, proprietary cheminformatics platform, called
the iResearch System, to this equation. Life scientists use the iResearch
System to accomplish in seconds the Herculean task of comparing large databases
of chemical structures and identify compounds that meet certain criteria. In
addition, ChemNavigator has working relationships with more than 30
international chemistry suppliers and is the source for the world's largest
collection of accessible drug-like compounds. It is important to note that all
the compounds in ChemNavigator's library are commercially accessible, meaning
they have been made at least once before, as opposed to virtual compounds that
are created using computer models and sometimes cannot be recreated in the
laboratory.
Ad Emmen [News on Advanced IT] [Calendar] [Analysis] [IT in Medicine] |
 |